Caroline Billingsley, MD
Gynecologic Oncology · Cincinnati, OHNPI 1619136082
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $713 of the $812 with a category attached, or 87.7%. It is spread thinly across 11 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gynecologic oncology clinicians in OH, where the typical reported total is $1,215.
Across 23 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$173
- AstraZeneca$161
- AbbVie$124
- Genmab U.S., Inc.$106
- GSK$84
- Intuitive Surgical$55
- plus $109 from 5 others
Across 44 payments — averaging $11,995 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$338K
- Merck$119K
- Clovis Oncology, Inc.$42K
- AstraZeneca$23K
- Pharmaand GmbH$5K
What the payments were for
- Food & beverage$71388%
- Education$10012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $173 |
| AstraZeneca | 2 | $161 |
| AbbVie | 4 | $124 |
| Genmab U.S., Inc. | 1 | $106 |
| GSK | 1 | $84 |
| Intuitive Surgical | 1 | $55 |
| Immunogen, Inc. | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$106
How this compares
$812 in reported general payments places this provider in the 40th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 32 | $248 |
| Oxycodone Hcl | 31 | $112 |
| Ibuprofen | 23 | $89 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $68 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Cincinnati
- Thomas HerzogCincinnati$585K
- Amanda JacksonCincinnati$92K
- Leeya PinderCincinnati$14K
- Ajit GubbiCincinnati$12K
- Eric EisenhauerCincinnati$9K
- Kevin SchulerCincinnati$2K
- Jack BasilCincinnati$382
- James PavelkaCincinnati$33
- David OmalleyHilliard$650K
- Floortje BackesHilliard$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.